Inhibitory role of plasminogen activator inhibitor-1 in invasion and proliferation of HLE hepatocellular carcinoma cells

Japanese Journal of Cancer Research

Volumn 90, Issue 7, 1999, Pages 747-752

  Morita, Yasushi ^a   Hayashi, Yoshitake ^a   Kanamaru, Taichi ^a   Itoh, Takashi ^a   Suzuki, Satoshi ^a   Yamamoto, Masahiro ^a   Kuroda, Yoshikazu ^a   Itoh, Hiroshi ^a  

^a KOBE UNIVERSITY   (Japan)

Author keywords

Antisense; Hepatocellular carcinoma; Invasion; Plasminogen activator inhibitor 1; Proliferation

Indexed keywords

COMPLEMENTARY RNA; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; UROKINASE;

ARTICLE; CELL INVASION; CELL PROLIFERATION; CELL SHAPE; CONTROLLED STUDY; DNA TRANSFECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NORTHERN BLOTTING; PRIORITY JOURNAL;

EID: 0032779919     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1999.tb00810.x     Document Type: Article

References (26)

1. Nakajima, M. and Chop, A. M. Tumor invasion and extracellular matrix degradative enzyme: regulation of activity by organ factors. Semin. Cancer Biol., 2, 115-127 (1991).
2. Tryggvason, K., Hoyhtya, M. and Salo, T. Proteolytic degradation of extracellular matrix in tumor invasion. Biochim. Biophys. Acta, 907, 191-217 (1987).
3. Liotta, L. A., Steeg, P. S. and Stetler-Stevenson, W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64, 327-336 (1991).
4. Danø, K., Andreasen, P. A., Grøndahl-Hansen, J., Kristensen, P., Nielsen, L. S. and Skriver, L. Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res., 44, 139-266 (1985).
5. Mars, W. M., Kim, T. H., Stolz, D. B., Liu, M. L. and Michalopoulos, G. K. Presence of urokinase in serum-free primary rat hepatocyte cultures and its role in activating hepatocyte growth factor. Cancer Res., 56, 2837-2843 (1996).
6. Jeffers, M., Rong, S. and Woude, G. F. V. Enhanced tumor-igenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signaling in human cells concomitant with induction of the urokinase proteolysis network. Mol. Cell. Biol., 16, 1115-1125 (1996).
7. Andreasen, P. A., Georg, B., Lund, L. R., Riccio, A. and Stacey, S. N. Plasminogen activator inhibitors: hormonally regulated serpins. Mol. Cell. Endocrinol., 68, 1-19 (1990).
8. Kruithof, E. K. O. Plasminogen activator inhibitors - a review. Enzyme, 40, 113-121 (1988).
9. Montogomery, A. M. P., Declerck, Y. A., Lamgley, K. E., Reisfeld, R. A. and Mueller, B. M. Melanoma-mediated dissolution of extracellular matrix: contribution of urokinase-dependent and metalloproteinase-dependent proteolytic pathways. Cancer Res., 53, 693-700 (1993).
10. Laug, W. E., Cao, X. R., Yu, Y. B., Shimada, H. and Kryithof, E. K. O. Inhibition of invasion of HT1080 sarcoma cells expressing recombinant plasminogen activator inhibitor 2. Cancer Res., 53, 6051 -6057 (1993).
11. Grøndahl-Hansen, J., Christensen, I. J., Rosenquist, C., Brunner, N., Mouridsen, H. T., Danø, K. and Blichert-Toft, M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res., 53, 2513-2521 (1993).
12. Nekarda, H., Schmitt, M., Ulm, K., Wenninger, A., Vogelsang, H., Becker, K., Roder, J. D., Fink, U. and Siewert, J. R. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res., 54, 2900-2907 (1994).
13. Pedersen, H., Brunner, N., Francis, D., Osterlind, K., Rønne, E., Hansen, H. H., Danø, K. and Grøndahl-Hansen, J. Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res., 54, 4671-4675 (1994).
14. Deng, G., Curriden, S. A., Wang, S., Rosenberg, S. and Loskutoff, D. J. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J. Cell Biol., 134, 1563-1571 (1996).
15. Waltz, D. A., Natkin, L. R., Fujita, R. M., Wei, Y. and Chapman, H. A. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J. Clin. Invest., 100, 58-67 (1997).
16. Soff, G. A., Sanderowitz, J., Gately, S., Verrusio, E., Weiss, I., Brem, S. and Kwaan, H. C. Expression of plasminogen activator inhibitor type1 by human prostate carcinoma cells inhibits primary tumor growth. J. Clin. Invest., 96, 2593-2600 (1995).
17. Alizadeh, H., Ma, D., Berman, M., Bellinham, D., Comerford, S. A., Gething, M. J. H., Sambrook, J. F. and Niederkorn, J. Y. Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas. Curr. Eye Res., 14, 449-458 (1995).
18. Morita, Y., Hayashi, Y., Wang, Y., Kanamaru, T., Suzuki, S., Kawasaki, K., Ohta, K., Yamamoto, M., Saitoh, Y., Itoh, H. and Doe, W. F. Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma. Hepatology, 25, 856-861 (1997).
19. Lee, F., Mulligan, R., Berg, P. and Ringold, G. Glucocorticoids regulate expression of dihydrofolate reductase cDNA in mouse mammary tumor virus chimaeric plasmids. Nature, 294, 228-232 (1981).
20. Cajot, J. F., Bamat, J., Bergonzelli, G. E., Kruithof, E. K. O., Medcalf, R. L., Testuz, J. and Sordat, B. Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cell. Proc. Natl. Acad. Sci. USA, 87, 6939-6943 (1990).
21. Ponton, A., Coulombe, B. and Skuo, D. Decreased expression of tissue inhibitor of metalloproteinases in metastatic tumor cells leading to increased levels of collagenase activity. Cancer Res., 51, 2138-2143 (1991).
22. Pappot, H., Gardsvoll, H., Romer, J., Pedersen, A. N., Grøndahl-Hansen, J., Pyke, C. and Brunner, N. Plasminogen activator inhibitor type 1 in cancer: therapeutic and prognostic implications. Biol. Chem. Hoppe Seyler, 376, 259-267 (1995).
23. Mimuro, J., Schleef, R. and Loskutoff, D. J. Extracellular matrix of cultured bovine aortic endothelial cells contains functionally active type 1 plasminogen activator inhibitor. Blood, 70, 721-728 (1987).
24. Jankun, J., Keck, R. W., Skrzypczak-Jankun, E. and Swiercz, R. Inhibitors of urokinase reduce size of prostate cancer xenografts in severe combined immunodeficient mice. Cancer Res., 57, 559-563 (1997).
25. Billstrom, A., Hartley-Asp, B., Lancander, I., Batra, S. and Astedt, B. The urokinase inhibitor p-aminobenzamidine inhibits growth of a human prostate tumor in SCID mice. Int. J. Cancer, 61, 542-547 (1995).
26. Rifkin, D. B., Gleizes, P. E., Harpel, J., Nunes, I., Mungen, J., Mazzieri, R. and Noguera, I. Plasminogen/plasminogen activator and growth factor activation. Ciba Found Symp., 212, 105-115 (1997).